8-KRegulation FD

ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Sep 23, 2005)

Filed September 23, 2005For Securities:ABT

Summary

This 8-K filing from Abbott Laboratories (ABT) on September 23, 2005, primarily addresses a recent U.S. District Court ruling concerning Abbott's Ultane® (sevoflurane) patent infringement case against Baxter. While the court upheld the validity of Abbott's patent, it found that Baxter did not infringe upon it. Abbott intends to pursue an expedited appeal of this decision, indicating their commitment to defending their intellectual property in this key product area. Importantly for investors, Abbott stated that this ruling has no impact on their previously issued 2005 earnings per share guidance, suggesting the financial implications are manageable or already accounted for. Baxter's ability to market sevoflurane remains restricted in most regions until December 11, 2005, providing Abbott with continued market protection in the interim. Abbott is also pursuing a separate lawsuit against Baxter related to additional sevoflurane formulations.

Key Highlights

  • 1Abbott Laboratories will appeal a U.S. District Court ruling that found their sevoflurane patent valid but not infringed by Baxter.
  • 2The company is requesting an expedited appeal to the Court of Appeals for the Federal Circuit.
  • 3Baxter is prohibited from marketing sevoflurane globally, except in China, Japan, and Korea, until December 11, 2005, due to a prior ruling.
  • 4Abbott is pursuing a second lawsuit against Baxter concerning additional sevoflurane formulations.
  • 5The court ruling is stated to have no impact on Abbott's previously provided 2005 earnings per share guidance.
  • 6The filing is made under Regulation FD and is furnished, not filed, meaning it won't be incorporated into registration statements unless specifically noted.

Frequently Asked Questions

The main reason for this 8-K filing is to disclose Abbott Laboratories' intention to appeal a U.S. District Court ruling in a patent infringement case concerning their product Ultane® (sevoflurane) against Baxter. While Abbott's patent was deemed valid, the court ruled that Baxter did not infringe it.

Abbott Laboratories explicitly stated that this ruling has no impact on their previously provided 2005 earnings per share guidance, indicating that the financial implications are either minor, already factored into projections, or covered by other strategies.

Baxter is currently prohibited from marketing sevoflurane worldwide, with the exception of China, Japan, and Korea, until December 11, 2005. This restriction is a result of a previous court ruling, offering Abbott continued market exclusivity in most regions for the time being.

In addition to appealing the current ruling, Abbott Laboratories is also proceeding with a second lawsuit against Baxter based on additional patents related to sevoflurane formulations, demonstrating a multi-pronged approach to protecting their intellectual property in this market.